Top View
- Open Full Page
- Siltuximab) for Injection, for Intravenous Use Severe Hypersensitivity Reaction to Siltuximab Or Any of the Excipients in Initial U.S
- Diagnosis and Management of Castleman Disease Blastic
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- (INN) for Biological and Biotechnological Substances
- Anti-IL6R: Tocilizumab, Satralizumab, Sarilumab, Olokizumab, Vobarilizumab Anti-IL6: Siltuximab, Sirukumab, Clazakizumab
- HOPA News Volume 11, Issue 3, 2014
- Extracorporeal Human Whole Blood in Motion, As a Tool to Predict First
- Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: a Systematic Review of Agents Under Clinical Development
- Supplementary File 1 (PDF, 469 Kib)
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Cardiotoxicity of Novel Targeted Hematological Therapies
- New Drug Update
- Siltuximab (Sylvant) National Drug Monograph January 2016 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives
- Multicentric Castleman Disease FDA Approval
- Adult Antiemetic Management of Chemotherapy-Induced Nausea
- (12) United States Patent (10) Patent No.: US 9.295,731 B2 Nguyen (45) Date of Patent: Mar
- Ez-Minutes February-April 2013
- Oncology Medications Policy (1403)
- Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment MAURIEN D
- Annex I Summary of Product Characteristics
- Siltuximab (Sylvant)
- Oncology Therapy for the Generalist
- Personalizing Medicine in Head and Neck Squamous Cell Carcinoma: the Rationale for Combination Therapies
- Chimeric Antibody
- Castleman Disease in the 21St Century: an Update on Diagnosis, Assessment, and Therapy
- Pitfalls in Oncology Drug Development
- (NCCN Guidelines®) Non-Hodgkin's Lymphomas
- Sylvant™ (Siltuximab) (Intravenous) -E- Document Number: IC-0479 Last Review Date: 02/02/2021 Date of Origin: 06/03/2019 Dates Reviewed: 06/2019, 02/2020, 02/2021
- Changes to Cancer Care Quality Program Effective May 17, 2021
- 2192.Full.Pdf
- Oncology and Chemo-Support Drug List
- Non-Self-Injectables the Following Codes Require Precertification for GHI PPO City of New York Employees/ Non-Medicare-Eligible Retirees with GHI PPO Benefits
- Pan-Canadian Oncology Drug Review Final Clinical Guidance Report
- (INN) for Biological and Biotechnological Substances
- Clinical Cancer Cancer Therapy: Clinical Research
- Global Oncology
- Effects of Immunomodulatory Drugs on Depressive Symptoms: a Mega-Analysis of Randomized, Placebo-Controlled Clinical Trials in Inflammatory Disorders
- Working Minutes of the Ephmra Classification Committee
- Do Not Tube List
- NCCN Guidelines for B-Cell Lymphomas V.1.2020 – Interim – 12/18/19
- Assessment of the Evolution of Cancer Treatment Therapies
- 125496Orig1s000
- Cytokine Release Syndrome Associated with T-Cell-Based Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and Treatment
- Castleman Disease, Alemtuzumab
- Specialty Pharmacy Infusion Site of Care Benefit Preauthorization Drug List
- Current Insights Into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade
- Emetogenic Potential of Antineoplastic Agents
- CALIFORNIA Provider Communications
- Appendix to Provincial Systemic Therapy Policy III-60
- A Case of Idiopathic Multicentric Castleman Disease in an Alemtuzumab-Treated Patient with MS
- Sylvant, INN: Siltuximab
- BC CANCER CHEMOTHERAPY PREPARATION and STABILITY CHART DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative
- Identification of Targets for Rational Pharmacological Therapy in Childhood Craniopharyngioma Jacob M